Benzinga | Oct 20, 2021 06:26AM EDT

Merck Recalls One Lot Of Cubicin Antibiotic Over Glass Particles Presence In Vials

* Merck & Co Inc (NYSE:MRK) is voluntarily recalling one lot of Cubicin (daptomycin for injection) 500 mg with expiry June 2022.

* Approximately 22,000 vials will be affected by this recall.

* The recall was initiated after a customer complaint reported that a glass piece was found in a vial of Cubicin after reconstitution.

* If used by the patient, local irritation or swelling at the infusion site may occur. More serious potential outcomes include blockage and clotting in blood vessels, life-threatening if a critical organ is affected.

* Other clinical consequences could include prolonged hospitalization.

* Cubicin is a lipopeptide antibacterial indicated for complicated skin and skin structure infections (cSSSI) in adult and pediatric patients.

* Price Action: MRK shares are up 0.40% at $79.81 during the premarket session on the last check Wednesday.